| Randomized, double-blind, placebo-controlled, multi-dose phase 2 study to determine the efficacy, safety and tolerability of AMG 162 in the treatment of postmenopausal women with low bone mineral density. Amgen, 06/2002-05/2007.
Multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of zoledronic acid in the treatment of osteoporosis in postmenopausal women taking calcium and vitamin D. Novartis Pharmaceuticals, 06/2002-06/2006, 3-year extension 01/2006-05/2009.
Randomized, double-blind, placebo-controlled, parallel group, multicenter, two-year Phase III study to determine the efficacy of risedronate therapy administered 35 mg once a week in men with osteoporosis. Procter & Gamble Pharmaceuticals, 07/2003-07/2005. 2-year open-label extension 05/2005-05/2007.
A randomized, double-blind, parallel-group study to evaluate and compare the effects of once-weekly alendronate (Fosamax®) and daily raloxifene (Evista®) on bone mineral density on postmenopausal women who have recently discontinued estrogen therapy (ARCADE -- Alendronate and Raloxifene Comparison After Discontinuing Estrogen-study), extension with open-label Fosamax for 1 year. Oregon Osteoporosis Center and Merck, 08/2003-07/2006.
Observational Study Direct Assessment of Non-Vertebral Fractures in Community Experience. Eli Lilly and company 03/2004-12/2010.
Open-label study to determine how prior therapy with alendronate or risedronate in post menopausal women with osteoporosis influences the clinical effectiveness of teriparatide. sanofi-aventis. 10/2004-07/2006.
A randomized, multicenter, double-blind, double-dummy, parallel group study to determine the efficacy & safety of intravenous zoledronic acid 5 mg annually compared to oral alendronate 70 mg weekly for the treatment of osteoporosis in men. Novartis Pharmaceuticals, 06/2004-08/2007. | 
